Stock Analysis
Exelixis, Inc. (EXEL) Stock Analysis
Exelixis, Inc. (EXEL) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Exelixis, Inc. (EXEL) currently has an AIQ Score of 82/100, indicating a very bullish setup. Momentum is the strongest factor at 91/100. Quality is the weakest current factor at 75/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
EXEL at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $69.00 |
| AIQ Score | 82/100 |
| Overall View | Very Bullish |
| Technical Analysis Consensus | Buy |
| Market Cap | $17.03B |
| P/E Ratio (TTM) | 20 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $0.88 |
| Revenue (Q3 FY2026) | $658.7M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.61 |
| Volume | 1.52M |
| 52-week range | $39.71-$73.69 |
| RSI 14 | 58.61 |
| 50-Day SMA | $62.29 |
| 200-Day SMA | $52.24 |
| Analyst Price Target | $58.67 |
| Next Earnings | Feb 9, 2027 |
EXELExelixis, Inc.
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum91
- Value79
- Quality75
- Risk resilience77
- Sentiment—
EXEL Stock Analysis Summary
Exelixis, Inc. (EXEL) currently has an AIQ Score of 82/100, indicating a very bullish setup. Momentum is the strongest factor at 91/100. Quality is the weakest current factor at 75/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a very bullish regime, EXEL has AIQ Score of 82/100 with Momentum base of 91/100 and fading Quality at 75/100. Wait for component alignment before adding exposure.
Healthcare · -1.20% stock move · EXEL classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is EXEL Bullish or Bearish Right Now?
EXEL currently has a very bullish overall setup. Momentum is the strongest factor at 91/100, while Quality is weakest at 75/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 75/100.
- - Momentum is constructive at 91/100.
- - Risk Resilience is supportive at 77/100.
- - Price is +10.78% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (27 vs 12).
- - Analyst target implies -14.98% downside from the latest quote.
Current Consensus
EXEL's Technical Analysis Consensus is currently Buy, with 27 buy, 7 neutral, and 12 sell votes. EXEL's 14-day RSI is 58.61, which places the stock in a constructive momentum range. EXEL's beta is 0.61, indicating lower market sensitivity than the broad market.
What Changed in EXEL?
The largest recent change in EXEL is Momentum moving down by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the EXEL Outlook?
The current very bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
EXEL Decision Framework
Public evidence layers, setup checks, and risk context for Exelixis, Inc..
Exelixis, Inc. (EXEL) Stock Analysis
Exelixis, Inc. has an AIQ Score of 82/100 in a Very Bullish regime. Momentum is strongest at 91/100. Beta is 0.61, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | EXEL is in a Very Bullish AIQ regime with score 82/100. |
| Signal Conflict | The primary conflict is that momentum leads at 91/100 while quality lags at 75/100. |
| Factor Evidence | Momentum 91/100 · Value 79/100 · Quality 75/100 · Risk 77/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 91/100.
Momentum is 91/100 and RSI (14) is 58.6.
EXEL is in a Very Bullish regime at 82/100.
Risk factor is 77/100 with beta 0.61 and annual volatility 33.9%.
Current conflict: momentum leads at 91/100 while quality lags at 75/100.
EXEL Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
EXEL Fundamentals
EXEL valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
EXEL Technical Analysis
EXEL technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
EXEL Stock Catalysts
Track EXEL earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
EXEL Dividend Analysis
EXEL dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
EXEL Financial Data
EXEL revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
EXEL Risk Analysis
EXEL volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
EXEL Stock News
EXEL stock news, market tone, recent headlines, and catalyst context.
EXEL vs Biotechnology Peers
Current peer cohort: EXEL · FTRE · GMAB · HALO · HRMY. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| EXEL Current stock | 82/100 | 79/100 | 91/100 | 77/100 | 1.5 | 33.90% | Current |
| FTRE Fortrea Holdings Inc. | 75/100 | 93/100 | 88/100 | 41/100 | 1.29 | 67.32% | EXEL vs FTRE |
| GMAB Genmab A/S | 77/100 | 71/100 | 94/100 | 58/100 | 1.29 | 45.85% | EXEL vs GMAB |
| HALO Halozyme Therapeutics, Inc. | 78/100 | 76/100 | 84/100 | 63/100 | 0.95 | 41.04% | EXEL vs HALO |
| HRMY Harmony Biosciences Holdings, Inc. | 73/100 | 89/100 | 66/100 | 63/100 | 0.07 | 40.59% | EXEL vs HRMY |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for EXEL: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Oct 2, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching EXEL
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for EXEL
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
EXEL Stock FAQ
What is EXEL stock price today?
Exelixis, Inc.'s current stock price is $69.00. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is EXEL bullish or bearish right now?
EXEL's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is EXEL's market cap?
EXEL's market cap is $17.03B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is EXEL's current P/E ratio?
EXEL's current P/E ratio is 20 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is EXEL's RSI?
EXEL's 14-day RSI is 58.61 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is EXEL above its 50-day and 200-day moving averages?
EXEL is 10.78% from its 50-day SMA and 32.07% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is EXEL's next earnings date?
EXEL's next earnings date is currently listed as Feb 9, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does EXEL pay a dividend?
EXEL's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.